- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Scott Tagawa, MD, MS, FACP | Authors
Articles
Future Directions in Prostate Cancer and Clinical Pearls for Clinicians
April 15, 2022
Video
Scott Tagawa, MD, MS, FACP wraps up by discussing how he envisions the future of prostate cancer and offers advice to community oncologists treating patients with the disease.
Potential Barriers and Challenges to Use of Radiotherapy in Prostate Cancer
April 15, 2022
Video
An overview of the barriers and challenges that patients, caregivers, clinicians, and other healthcare personnel may face when radiation-based therapies are used for treatment of prostate cancer.
Potential Use of Lu 177 Vipivotide Tetraxetan in Non-VISION Prostate Cancer Settings
April 15, 2022
Video
Scott Tagawa, MD, MS, FACP, discusses other prostate cancer settings besides metastatic CRPC where Lu 177 vipivotide tetraxetan could potentially be useful, and touches on ongoing clinical trials in these settings.
Safety Data from the VISION Trial
April 15, 2022
Video
A discussion of key safety data on the VISION trial.
Single-Agent versus Combination Therapy in Metastatic Prostate Cancer
April 15, 2022
Video
Scott Tagawa, MD, MS, FACP, compares the use of single-agent regimens versus combination regimens in the treatment of metastatic prostate cancer.
Efficacy Data from the VISION Trial of Lu 177 Vipivotide Tetraxetan
April 15, 2022
Video
Scott Tagawa, MD, MS, FACP, reviews key efficacy data from the VISION trial of Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer (CRPC).